Related Experiment Video
Updated: May 16, 2026

Comprehensive Profiling of Dopamine Regulation in Substantia Nigra and Ventral Tegmental Area
Published on: August 10, 2012
Expression and activity of nitric oxide synthase isoforms in methamphetamine-induced striatal dopamine toxicity
Danielle M Friend1, Jong H Son, Kristen A Keefe
1Interdepartmental Program in Neuroscience, University of Utah, Salt Lake City, UT 84112, USA.
Abstract:
Nitric oxide is implicated in methamphetamine (METH)-induced neurotoxicity; however, the source of the nitric oxide has not been identified. Previous work has also revealed that animals with partial dopamine loss induced by a neurotoxic regimen of methamphetamine fail to exhibit further decreases in striatal dopamine when re-exposed to methamphetamine 7-30 days later. The current study examined nitric oxide synthase expression and activity and protein nitration in striata of animals administered saline or neurotoxic regimens of methamphetamine at postnatal days 60 and/or 90, resulting in four treatment groups: Saline:Saline, METH:Saline, Saline:METH, and METH:METH. Acute administration of methamphetamine on postnatal day 90 (Saline:METH and METH:METH) increased nitric oxide production, as evidenced by increased protein nitration. Methamphetamine did not, however, change the expression of endothelial or inducible isoforms of nitric oxide synthase, nor did it change the number of cells positive for neuronal nitric oxide synthase mRNA expression or the amount of neuronal nitric oxide synthase mRNA per cell. However, nitric oxide synthase activity in striatal interneurons was increased in the Saline:METH and METH:METH animals. These data suggest that increased nitric oxide production after a neurotoxic regimen of methamphetamine results from increased nitric oxide synthase activity, rather than an induction of mRNA, and that constitutively expressed neuronal nitric oxide synthase is the most likely source of nitric oxide after methamphetamine administration. Of interest, animals rendered resistant to further methamphetamine-induced dopamine depletions still show equivalent degrees of methamphetamine-induced nitric oxide production, suggesting that nitric oxide production alone in response to methamphetamine is not sufficient to induce acute neurotoxic injury.
Insights
Methamphetamine (METH) increases nitric oxide (NO) production via enhanced NO synthase activity, not new gene expression. This NO production does not cause further dopamine loss in METH-resistant animals.
Area of Science:
- Neuroscience
- Pharmacology
- Toxicology
Background:
- Nitric oxide (NO) is linked to methamphetamine (METH)-induced neurotoxicity.
- The specific source of NO in METH neurotoxicity remains unidentified.
- METH-resistant animals do not experience further dopamine depletion upon re-exposure.
Purpose of the Study:
- To investigate the source and regulation of nitric oxide production following methamphetamine administration.
- To determine if nitric oxide synthase (NOS) expression or activity is altered by METH.
- To assess the role of NO in METH-induced neurotoxicity and dopamine depletion.
Main Methods:
- Animals received saline or METH regimens at postnatal days 60 and/or 90.
- Examined NOS expression (eNOS, iNOS, nNOS mRNA), NOS activity, and protein nitration in striata.
- Compared four groups: Saline:Saline, METH:Saline, Saline:METH, METH:METH.
Main Results:
- Acute METH administration increased NO production, indicated by elevated protein nitration.
- NOS expression (eNOS, iNOS, nNOS mRNA) remained unchanged.
- NOS activity in striatal interneurons increased, suggesting a role for constitutive nNOS.
Conclusions:
- Increased NO production post-METH stems from enhanced NOS activity, not altered gene expression.
- Constitutively expressed neuronal NOS is the likely source of NO after METH exposure.
- NO production alone is insufficient to cause acute METH neurotoxicity, as METH-resistant animals still produce NO.
Related Concept Videos
Drugs Affecting Neurotransmitter Synthesis
Nitric Oxide Signaling Pathway
Adrenergic Agonists: Indirect-Acting Agents
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...
Neurochemical Transmission: Sites of Drug Action

